SREBP1 as a Potential Biomarker Promotes Cell Proliferation and Invasion in Thyroid Cancer

Thyroid Cancer Clinical Trial

Official title:

SREBP1 as a Potential Biomarker Promotes Cell Proliferation and Invasion in Thyroid Cancer

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04072731
• Other study ID #: SBQLL-2016-015
• Status: Completed
• Start date: January 16, 2016
• Est. completion date: January 1, 2018

Study information

• Verified date: August 2019
• Source: People's Hospital of Zhengzhou University
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

In this study, the investigators detected the expression of SREBP1 in thyroid cancer tissues, explored the biological functions of SREBP1 in thyroid cancer cells.

Description:

qRT-PCR and immunohistochemistry were used to detect the expression of SREBP1 in 96 pairs thyroid cancer tissues and the adjacent normal tissues. The following methods, including the MTS, colony-forming assay, flow cytometry and hoechst staining were used to detect the biological function of thyroid cancer cells based on SREBP1 interference or not.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 140
• Est. completion date: January 1, 2018
• Est. primary completion date: July 30, 2017
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 60 Years

Eligibility

Inclusion Criteria:

Clinical diagnosis of thyroid cancer Reciving thyroidectomy surgery No experience of radiation therapy Nice treatment compliance and follow-up regularly

Exclusion Criteria:

Prior history of malignancy ; Radiotherapy history, chemotherapy history; Serious concomitant diseases ; Chronic renal insufficiency and liver dysfunction

Related Conditions & MeSH terms

• Thyroid Cancer
• Thyroid Diseases
• Thyroid Neoplasms

Intervention

Other:
• pathologic
All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.

Locations

Country	Name	City	State
China	the Affiliated Cancer Hospital of Xiangya Medical School	Changsha	Hunan

Sponsors (1)

Lead Sponsor	Collaborator
People's Hospital of Zhengzhou University

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	progression-free survival	disease recurrent of progression	average 5 years
Secondary	theraputic efficacy	According to the ATA guideline, patients were divided into four group, including excellent response (ER),indeterminate response (IDR), biochemical incomplete response (BIR), structural incomplete response (SIR) after surgery and radioiodine treatment.	average 18 months